Analysts Set $15.00 Target Price for Sunshine Heart Inc (CHFS)

Shares of Sunshine Heart Inc (NASDAQ:CHFS) have earned a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the stock, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy recommendation.

Analysts have set a one year consensus price objective of $15.00 for the company, according to Zacks. Zacks has also given Sunshine Heart an industry rank of 166 out of 265 based on the ratings given to its competitors.

Several research firms recently issued reports on CHFS. ValuEngine upgraded shares of Sunshine Heart from a “strong sell” rating to a “sell” rating in a research report on Tuesday, October 31st. Zacks Investment Research upgraded shares of Sunshine Heart from a “hold” rating to a “buy” rating and set a $4.00 price target on the stock in a research report on Monday, January 8th.

Shares of Sunshine Heart (NASDAQ:CHFS) traded up $0.22 on Monday, hitting $3.25. 183,029 shares of the stock traded hands, compared to its average volume of 636,111. The company has a market capitalization of $5.46, a PE ratio of -0.02 and a beta of 2.34. Sunshine Heart has a 12 month low of $2.87 and a 12 month high of $109.80.

ILLEGAL ACTIVITY WARNING: This article was first posted by American Banking News and is owned by of American Banking News. If you are accessing this article on another website, it was illegally stolen and reposted in violation of United States and international copyright and trademark law. The correct version of this article can be accessed at

Sunshine Heart Company Profile

CHF Solutions, Inc, an early-stage medical device company, develops cardiac and coronary disease products primarily in the United States. It focused on commercializing the Aquadex FlexFlow system, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization.

Get a free copy of the Zacks research report on Sunshine Heart (CHFS)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Sunshine Heart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Heart and related companies with's FREE daily email newsletter.

Leave a Reply